| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/14/2007 | CN1300139C Haptens, immunogens, antibodies and conjugates for 2-oxo-3-hydroxy LSD |
| 02/14/2007 | CN1299776C Nano granules of ampyhiphilic three block copolymer, preparation method and application thereof |
| 02/14/2007 | CN1299775C Injectable pharmaceutical slow-release carrier and preparation method thereof |
| 02/14/2007 | CN1299766C Use of TGF-beta and growth factor in treatment and prevention of intestinal mucosa diseases |
| 02/14/2007 | CN1299764C Preparing method of liposome endothelial chalone |
| 02/14/2007 | CN1299691C Telithromycin suspension with a masked taste |
| 02/14/2007 | CN1299686C Combination of semisolid framework preparation of progesterone |
| 02/13/2007 | US7176278 Modified transferrin fusion proteins |
| 02/13/2007 | US7176256 Reacting by crosslinking a first synthetic polymer containing multiple nucleophilic groups such as amino groups, with a second synthetic polymer containing multiple electrophilic groups such as succinimidyl groups to covalently bind them; use to prevent surgical adhesions, coat implants |
| 02/13/2007 | US7176221 Low dose pharmaceutical composition having uniform drug distribution and potency |
| 02/13/2007 | US7176178 Protein H and its fragments/derivatives are capable of interacting with nucleophosmin/B23, actin, NPM/B23, protein SET or hnRNP A2/B1 |
| 02/13/2007 | US7175857 Coatings with binders and excipients for drugs using copolymers for skins |
| 02/13/2007 | US7175856 Mixing drug with arginine; reduction of bitter taste |
| 02/13/2007 | US7175854 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 02/13/2007 | US7175853 Therapeutic system which can be moisture-activated |
| 02/13/2007 | US7175850 Formulation for topical non-invasive application in vivo |
| 02/13/2007 | CA2233501C Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| 02/13/2007 | CA2084987C Nucleic acid ligands |
| 02/08/2007 | WO2007016562A2 Formulations that inhibit protein aggregation |
| 02/08/2007 | WO2007016556A1 Multifunctional polymers for promotion of opsonization of target cells and organisms |
| 02/08/2007 | WO2007016306A2 HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF |
| 02/08/2007 | WO2007016160A2 Svct2 transporters expressed in blood brain barrier cells |
| 02/08/2007 | WO2007016018A2 Improved botulinum toxin compositions |
| 02/08/2007 | WO2007015510A1 Method for prevention of degradation of thermally unstable substance |
| 02/08/2007 | WO2007015453A1 Lotion preparation containing pyridonecarboxylic acid derivative |
| 02/08/2007 | WO2007015441A1 Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration |
| 02/08/2007 | WO2007015270A2 Novel controlled release compositions of selective serotonin reuptake inhibitors |
| 02/08/2007 | WO2007015107A2 Artificial platelets |
| 02/08/2007 | WO2007015105A2 Nanoparticles comprising antibacterial ligands |
| 02/08/2007 | WO2007014848A2 Stabilization of body-care and household products against degradation by uv radiation using merocyanine derivatives |
| 02/08/2007 | WO2007014784A2 Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation |
| 02/08/2007 | WO2007014744A2 C-terminal tnf-family ligand (ctl) -prodrug |
| 02/08/2007 | WO2007014476A1 Pharmaceutical composition containing indometacin and/or acemetacin |
| 02/08/2007 | WO2007014460A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2007014432A1 Peptide conjugate for oral delivery of hydrophilic peptide analgesics |
| 02/08/2007 | WO2006130799A3 Bioconjugation reactions for acylating polyethlene glycol reagents |
| 02/08/2007 | WO2006127779A3 Supplement composition and method of use for enhancement of insulin sensititivy |
| 02/08/2007 | WO2006111399A3 Highly porous polymeric materials comprising biologically active molecules via covalent grafting |
| 02/08/2007 | WO2006099514A9 Drug delivery compositions and related methods |
| 02/08/2007 | WO2006088576A3 Polypeptide formulations and methods for making, using and characterizing them |
| 02/08/2007 | WO2006076042A9 Novel hydrogels and uses thereof |
| 02/08/2007 | WO2006062732A3 Compounds acting at the centrosome |
| 02/08/2007 | WO2006042192A3 Relevance of achieved levels of markers of systemic inflammation following treatment |
| 02/08/2007 | WO2006020722A3 Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting |
| 02/08/2007 | WO2006010165A3 Compositions for multi-step delivery of hot-spots radiation to cancer cells |
| 02/08/2007 | WO2005107728A3 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 02/08/2007 | WO2003068934A3 Chimeric molecules for cleavage in a treated host |
| 02/08/2007 | US20070032441 treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 02/08/2007 | US20070032438 Pharmaceutical compositions containing taxanes and methods for preparing the pharmaceutical compositions |
| 02/08/2007 | US20070032408 Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds |
| 02/08/2007 | US20070032405 Branched water-soluble polymers and their conjugates |
| 02/08/2007 | US20070031965 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 02/08/2007 | US20070031887 Aqueous-based pharmaceutical composition |
| 02/08/2007 | US20070031502 Pharmaceutical composition for the treatment of acute disorders |
| 02/08/2007 | US20070031501 Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions |
| 02/08/2007 | US20070031500 Long-acting solid formulation comprising triptorelin acetate |
| 02/08/2007 | US20070031493 Pharmaceutical compositions |
| 02/08/2007 | US20070031485 Pharmaceutical composition having a cationic excipient |
| 02/08/2007 | US20070031484 Immunoliposomes that optimize internationalization into target cells |
| 02/08/2007 | US20070031483 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 02/08/2007 | US20070031479 Bioadhesive gel based on hydroxyethycellulose |
| 02/08/2007 | US20070031476 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) |
| 02/08/2007 | US20070031475 Nutritional composition with unsaturated fatty acids and trace elements |
| 02/08/2007 | US20070031460 micelles; cyclosporin A solubilized via fatty acid and/or fatty alcohol |
| 02/08/2007 | US20070031430 Varible domain of heavy chain antibodies; antitumor agents |
| 02/08/2007 | US20070031374 Treating cell proliferative disorders via administration of mixture comprising interleukin-21 and anti-cancer monoclonal antibody |
| 02/08/2007 | US20070031368 Chemokine conjugates |
| 02/08/2007 | US20070031344 Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| 02/08/2007 | US20070031335 Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| 02/08/2007 | US20070031334 Vitamin-targeted imaging agents |
| 02/08/2007 | US20070028801 cellulose hydrolyzates having an average polymerization degree of 150 to 450, microstructure particle sizes, an apparent specific volume of more than 7 cm3/g and a retention capacity for polyethylene glycol, useful as an excipient for medicines, foods or chemicals |
| 02/08/2007 | DE19930177B4 Intermolekular assoziierende Verbindungen und deren Verwendung Inter-molecular associative compounds and their use |
| 02/08/2007 | DE19858005B4 Synthetisches Nucleinsäure-Partikel Synthetic nucleic acid particles |
| 02/08/2007 | DE10260882B4 Dosieraerosole mit Sojalecithin als oberflächenaktiver Substanz und dessen Verwendung MDIs containing soy lecithin as a surfactant and its use |
| 02/08/2007 | CA2625917A1 Artificial platelets |
| 02/08/2007 | CA2617869A1 Nanoparticles comprising antibacterial ligands |
| 02/08/2007 | CA2617462A1 Cancerous disease modifying antibodies |
| 02/08/2007 | CA2617449A1 Peptide conjugate for oral delivery of hydrophilic peptide analgesics |
| 02/08/2007 | CA2617286A1 Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation |
| 02/08/2007 | CA2616987A1 Mutated pseudomonas exotoxins with reduced antigenicity |
| 02/08/2007 | CA2616957A1 Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation |
| 02/08/2007 | CA2615912A1 Lotion preparation containing pyridonecarboxylic acid derivative |
| 02/08/2007 | CA2615731A1 Formulations that inhibit protein aggregation |
| 02/08/2007 | CA2615688A1 Peroxide removal from drug delivery vehicle |
| 02/08/2007 | CA2615627A1 Methods for preparing polymeric reagents and compositions of polymeric reagents |
| 02/08/2007 | CA2603143A1 Improved botulinum toxin compositions |
| 02/08/2007 | CA2547043A1 A plasma source and applications thereof |
| 02/07/2007 | EP1749849A1 Materials having crosslinked polyrotaxane and process for producing these |
| 02/07/2007 | EP1749541A1 Thickener for ophthalmic use |
| 02/07/2007 | EP1749535A1 Remedy for diabetic neuropathy comprising gelatin gel as carrier |
| 02/07/2007 | EP1749520A1 Water-dispersible encapsulated sterols |
| 02/07/2007 | EP1749516A2 Lock and key micelles |
| 02/07/2007 | EP1749039A1 Low molecular weight polylactic acid polymers |
| 02/07/2007 | EP1749018A1 Methods and kits for stabilising, protecting and solubilising proteins |
| 02/07/2007 | EP1748796A2 Multilayered nanomedicine delivery system and method |
| 02/07/2007 | EP1748788A1 Hydrogel interferon formulations |
| 02/07/2007 | EP1748778A1 Controlled-release formulations containing vardenafil |
| 02/07/2007 | EP1748777A1 Controlled-release formulations containing vardenafil |
| 02/07/2007 | EP1748770A1 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| 02/07/2007 | EP1748765A1 Pharmaceutical suspension composition |